Full compliance with follow-up improves head and neck cancer survival

This article originally appeared here.
Share this content:
Full Adherence to Follow-Up Improves Head/Neck CA Survival
Full Adherence to Follow-Up Improves Head/Neck CA Survival

(HealthDay News) -- For patients with head and neck squamous cell carcinoma, compliance with posttreatment surveillance (PTS) is associated with survival, according to a study published online May 7 in JAMA Otolaryngology-Head & Neck Surgery.

Michael W. Deutschmann, M.D., from the University of Kansas Medical Center in Kansas City, and colleagues examined how compliance with follow-up affects clinical outcomes in a cohort of 332 patients with head and neck squamous cell carcinoma.

The researchers identified significant effects on survival for compliance with PTS (P = 0.001), U.S. Census tract income level (P = 0.001), and the distance patients travel for follow-up (P = 0.01). There were significant associations with an increased risk of death for more advanced disease (hazard ratio [HR], 1.76), middle and moderate census tract income level (HR, 1.64 and 1.90, respectively), and age (HR, 1.03). Compliance was also associated with tobacco cessation (P = 0.003) and distance that a patient lived from the medical center (P = 0.008).

"Patients had improved overall survival with full compliance of PTS as well as tobacco cessation," the authors write. "Compliance levels were significantly associated with smoking cessation and patients traveling greater than 200 miles for follow-up."

Full Text

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs